These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Soluble tumor necrosis factor receptor p55 predicts cytokinemia and systemic inflammatory response after cardiopulmonary bypass. el-Barbary M; Khabar KS Crit Care Med; 2002 Aug; 30(8):1712-6. PubMed ID: 12163781 [TBL] [Abstract][Full Text] [Related]
9. [Dynamic change of tumor necrosis factor and endothelin during perioperative period in patients undergoing coronary artery bypass grafting]. Wen S; Wang J; Zhang C Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(23):1450-2. PubMed ID: 11930620 [TBL] [Abstract][Full Text] [Related]
10. Plasma and urinary cytokine homeostasis and renal function during cardiac surgery without cardiopulmonary bypass. Gormley SM; McBride WT; Armstrong MA; McClean E; MacGowan SW; Campalani G; McMurray TJ Cytokine; 2002 Jan; 17(2):61-5. PubMed ID: 11886172 [TBL] [Abstract][Full Text] [Related]
11. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Horn EM; Widlitz AC; Barst RJ Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395 [TBL] [Abstract][Full Text] [Related]
12. Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Barst RJ Expert Opin Pharmacother; 2007 Jan; 8(1):95-109. PubMed ID: 17163810 [TBL] [Abstract][Full Text] [Related]
13. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992 [TBL] [Abstract][Full Text] [Related]
14. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Langleben D; Cacoub P Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744 [TBL] [Abstract][Full Text] [Related]
15. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N; J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324 [TBL] [Abstract][Full Text] [Related]
16. Prolonged anti-hypertensive effects of oral sitaxsentan, a selective ET(A) endothelin receptor antagonist, in spontaneoulsy hypertensive hamsters. Rubinstein I Cardiovasc Drugs Ther; 2006 Oct; 20(5):387-90. PubMed ID: 17043751 [TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukin-6, interleukin-8, interleukin-10, and tumor necrosis factor-α, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery. Gorjipour F; Totonchi Z; Gholampour Dehaki M; Hosseini S; Tirgarfakheri K; Mehrabanian M; Mortazian M; Arasteh Manesh S; Rahab M; Shafighnia S; Taiyari S; Gorjipour F Perfusion; 2019 Nov; 34(8):651-659. PubMed ID: 31027462 [TBL] [Abstract][Full Text] [Related]